L. lactis

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: digestion immunity inflammation

Research Overview

Across the abstracts, Lactococcus lactis research is most developed in three interconnected areas: (1) food fermentation and flavor biochemistry (starter-culture performance, volatile metabolite profiles, and strain-to-strain variability in dairy and plant-based matrices), (2) probiotic and antimicrobial functionality (survival/tolerance traits, adhesion/competition with pathogens, and bacteriocin biology—especially nisin), and (3) biomedical “live biotherapeutic” applications using L. lactis as a mucosal delivery vector for proteins or DNA (e.g., antigens, cytokines, enzymes) in animal models. A smaller but notable body of work also targets microbiota–gut–brain axis outcomes, including stress-related behavioral phenotypes in rodents, where L. lactis administration is linked to changes in serotonin metabolism and gut microbiome composition.

The strongest evidence supported by these abstracts is that L. lactis is a robust, safe, and versatile organism for food biotechnology and as a platform organism for engineered mucosal delivery in preclinical settings. Multiple studies show clear, reproducible strain-dependent effects on fermentation outcomes (volatile compounds, off-flavor removal, and dairy-like flavor generation such as diacetyl), indicating that isolate selection materially determines product chemistry and sensory potential. For health-related effects, the evidence is strongest at the preclinical/proof-of-concept level: certain dairy-derived L. lactis strains exhibit in vitro and cell-model features consistent with probiotic potential (acid/bile tolerance, aggregation properties, reduced pathogen adhesion), and nisin has well-established antibacterial activity with emerging immunomodulatory signals from diverse experimental models. Similarly, recombinant L. lactis vectors have demonstrated prophylactic/therapeutic effects in several animal models, supporting feasibility of mucosal delivery approaches.

Key gaps include translation and mechanistic resolution. Many reported benefits (pathogen exclusion, immunomodulation, gut–brain effects) remain largely supported by in vitro assays and animal models, with a need for well-controlled human clinical trials, standardized strain characterization, dosing, and endpoints. Mechanistically, more work is needed to connect specific L. lactis genotypes/metabolic pathways to host outcomes (e.g., defining causal mediators such as tryptophan/serotonin-related metabolites, immune signaling pathways, or bacteriocin-driven effects) and to disentangle direct microbial actions from broader microbiome shifts. In food systems, further research is warranted to generalize findings across matrices (dairy vs. plant-based), validate sensory impacts with trained panels/consumer studies, and optimize co-culture designs that reliably couple off-flavor mitigation with desirable flavor formation and nutritional improvements.

1. What conditions has L. lactis been studied for?

  • Stress-related depression/anxiety-like behavior and cognitive dysfunction (rodent model): chronic unpredictable/unforeseeable mild stress (CUMS) in mice; also examined in a serotonin-pathway genetic model (TPH2 knockout mice).

  • Allergic asthma / airway inflammation (mouse model; human biomarker comparison): extracellular vesicles (EVs) derived from Lactococcus lactis tested intranasally in allergic asthmatic mice; EV-specific antibodies measured in people with asthma vs healthy controls.

  • Type 2 diabetes (T2D) (mouse model): genetically engineered L. lactis designed to secrete GLP-1, with additional chemical/biopolymer modifications to improve survival/colonization, tested via oral administration in T2D mice.

  • Pathogen adhesion / gut barrier-related outcomes (in vitro cell model): dairy-isolated L. lactis strains tested for ability to inhibit adhesion of enteroinvasive E. coli and Salmonella Typhimurium to epithelial cells.

  • Immune modulation (general): a systematic review focused on nisin (a bacteriocin produced by some L. lactis strains) and its immunomodulatory properties in experimental models; also discusses effects of nisin-producing L. lactis strains on animal immune systems.

  • Mucosal delivery of therapeutics/vaccines (animal models): review describing recombinant L. lactis as a vector for therapeutic proteins/DNA vaccines, tested in models including HPV-16 tumor prophylaxis/therapy, partial prevention of β-lactoglobulin (BLG) allergy in mice, and regulation of body weight/food consumption in obese mice.

  • Food/fermentation applications with potential nutritional implications (food science): effects on volatile flavor compounds in fermented milk; co-culture fermentation of plant-based drinks to reduce off-flavors and generate dairy-like flavors; amino-acid related pathways (e.g., branched-chain amino acid biosynthesis) described.

2. Does it work in treating those conditions? Summarize the evidence.

  • CUMS depression/anxiety-like behavior and cognition (mice): In female CUMS mice, oral L. lactis E001-B-8 “significantly improved the cognitive behaviour of mice.” The abstract links benefits to improved 5-HT (serotonin) metabolism and modulation of gut microbiome composition, alongside changes reported in hippocampal autophagy, neurotransmitters, oxidative stress damage, and neuroinflammation. This is preclinical evidence (mouse model), not a human clinical trial.

  • Allergic asthma (mice; supportive human association): Intranasal treatment with L. lactis-derived EVs in allergic asthmatic mice reduced airway hyperresponsiveness, eosinophils, cytokine secretion, and mucus production, and shifted immune responses from Th2 toward Th1 via dendritic-cell IL-12 production. In humans, asthmatic patients had lower serum EV-specific IgG4 than healthy controls, and EV-IgG4 levels positively correlated with lung function (FEV…; abstract truncated). This supports biological plausibility and a potential association, but does not establish clinical efficacy of L. lactis or its EVs as a treatment in people.

  • Type 2 diabetes (mice; engineered strain): An engineered L. lactis secreting GLP-1, further modified to improve GI survival and colonization, produced “effective T2D treatment” in mice, improving glucose/lipid homeostasis, organ damage markers, and gut microbiota; multi-omics suggested liver pathway effects (lipid metabolism/oxidative regulation). This is preclinical and uses a genetically engineered product, so it cannot be assumed to apply to standard dietary/probiotic L. lactis strains.

  • Pathogen adhesion (in vitro): Several whey-starter L. lactis strains (A3, A5, I4, I7) competed with pathogens and showed protective effects in epithelial co-culture models against E. coli and S. Typhimurium adhesion. This suggests a potential mechanism for gut protection, but it is not clinical evidence.

  • Other therapeutic areas (reviews): Reviews describe successful testing of recombinant L. lactis vectors in multiple animal models (HPV-16 tumors, BLG allergy, obesity-related outcomes) and argue these approaches should be tested in human trials. However, the abstracts provided do not include results from completed human randomized controlled trials.

Bottom line: Across these abstracts, evidence for “treatment” effects is largely animal or in vitro, with limited human data (an asthma biomarker comparison). Efficacy in humans remains uncertain based on the provided abstracts.

3. What health benefits does it have?

  • Potential psychobiotic-like effects (preclinical): L. lactis E001-B-8 improved cognitive behavior in stressed mice, with proposed links to serotonin metabolism and gut microbiome modulation (microbiota–gut–brain axis).

  • Immune regulation / anti-inflammatory potential (preclinical): L. lactis-derived EVs reduced allergic airway inflammation in mice and promoted a Th2→Th1 shift via dendritic cell IL-12.

  • Antimicrobial/colonization resistance mechanisms: Some L. lactis strains can inhibit pathogen adhesion to epithelial cells (in vitro). Additionally, some strains produce nisin, a lantibiotic with broad activity against Gram-positive bacteria; the systematic review notes nisin may also have immunotropic effects beyond antibacterial activity (mechanisms not fully understood).

  • Probiotic-like properties (strain-dependent, in vitro/genomic): Dairy-derived strains showed survival in simulated gastric juice, bile tolerance, hydrophobicity, and auto-aggregation; a buffalo-milk isolate (Lac3) lacked detected virulence factors/acquired antibiotic resistance phenotypes and tolerated acid/bile/salt in vitro.

  • Therapeutic delivery platform (biotechnology concept): Recombinant L. lactis can be engineered to deliver antigens, cytokines, enzymes, or DNA at mucosal surfaces, with prophylactic/therapeutic effects shown in various animal models (e.g., HPV-16 tumor models, allergy model, obesity-related outcomes).

  • Food/fermentation-related benefits: Different L. lactis isolates alter volatile flavor profiles in fermented milk; co-cultures including L. lactis improved plant-based fermented beverages by helping generate dairy-like flavors (e.g., diacetyl, 3-methyl-1-butanol) and, in combination with another LAB, reduced off-flavors.

Important limitation: Many “health benefits” above are strain-specific and/or based on preclinical models; they should not be generalized to all L. lactis products.

4. Does it have any downsides or side effects?

  • Human side effects are not well characterized in these abstracts: None of the provided abstracts report rates of adverse events in human clinical trials for L. lactis supplementation.

  • Generally regarded as safe (GRAS) context: Multiple abstracts note L. lactis (as a LAB used in fermented foods) has a long history of safe consumption. However, “safe in foods” does not automatically equal “safe/effective as a therapeutic at high doses or via non-oral routes.”

  • Route/formulation matters: Some interventions described are not typical supplements (e.g., intranasal EV administration; genetically engineered GLP-1 secreting strains with chemical “gripper/shield”). Safety considerations for these approaches differ from standard fermented-food exposure.

  • Antibiotic resistance/virulence concerns appear low in specific strains studied: The Lac3 genome analysis reported no virulence factors or acquired antibiotic resistance phenotypes; whey-starter strains were reported safe by antibiotic susceptibility and lack of hemolytic activity. This is reassuring but cannot be assumed for all strains.

  • Potential immunologic uncertainty: Because EVs and bacteriocins (nisin) can modulate immune responses, there is a theoretical risk that effects could be context-dependent (beneficial in some inflammatory states, undesirable in others). The abstracts do not provide definitive safety outcomes for such scenarios.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

  • Serotonin-pathway genetics (preclinical): The depression/cognition study included TPH2 knockout mice (TPH2 is involved in brain serotonin synthesis). TPH2 KO CUMS mice had lower extracellular serotonin and worse cognitive dysfunction than CUMS mice, supporting a role for serotonin biology in the phenotype. The abstract reports that L. lactis E001-B-8 improved cognitive behavior in mice and was associated with improved 5-HT metabolism, but it does not clearly state whether the magnitude of benefit differed by genotype (TPH2 KO vs non-KO) or whether genotype predicts response.

  • No established human pharmacogenomic guidance: None of the abstracts provide evidence that specific human genetic variants predict benefit or harm from L. lactis (as a probiotic, EV product, or engineered therapeutic vector). At present, there is insufficient evidence to recommend L. lactis based on genotype in clinical practice.

  • Engineered strains introduce different considerations: For genetically engineered L. lactis delivering GLP-1 or DNA, host genetics could plausibly influence immune response or metabolic outcomes, but the abstracts do not evaluate pharmacogenomic stratification.

References

  1. 5-HT attenuates chronic stress-induced cognitive impairment in mice through intestinal flora disruption.
    Junxing Ma, Ran Wang, Yaoxing Chen, Zixu Wang, Yulan Dong (2023) - Journal of neuroinflammation
  2. Effect of different isolation sources ofLactococcus lactissubsp.lactison volatile metabolites in fermented milk
    Xia Yu, Yaru Sun, Xin Shen, Weicheng Li, Hongyu Cai (2024)
  3. Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines.
    Luis G Bermúdez-Humarán, Pascale Kharrat, Jean-Marc Chatel, Philippe Langella (2011) - Microbial cell factories
  4. AhR/IL-22 pathway as new target for the treatment of post-infectious irritable bowel syndrome symptoms.
    Maëva Meynier, Elodie Baudu, Nathalie Rolhion, Manon Defaye, Marjolène Straube, Valentine Daugey, Morgane Modoux, Ivan Wawrzyniak, Frédéric Delbac, Roamin Villéger, Mathieu Méleine, Esther Borras Nogues, Catherine Godfraind, Nicolas Barnich, Denis Ardid, Philippe Poirier, Harry Sokol, Jean-Marc Chatel, Philippe Langella, Valérie Livrelli, Mathilde Bonnet, Frédéric Antonio Carvalho (2022) - Gut microbes
  5. Lactococcus lactis HkyuLL 10 suppresses colorectal tumourigenesis and restores gut microbiota through its generated alpha-mannosidase.
    Anthony Chin Yang Su, Xiao Ding, Harry Cheuk Hay Lau, Xing Kang, Qing Li, Xueliang Wang, Yali Liu, Lanping Jiang, Yinghong Lu, Weixin Liu, Yanqiang Ding, Alvin Ho-Kwan Cheung, Ka Fai To, Jun Yu (2024) - Gut
  6. Probiotic Properties ofLactococcus lactisStrains Isolated from Natural Whey Starter Cultures
    Ida De Chiara, Rosangela Marasco, Milena Della Gala, Alessandra Fusco, Giovanna Donnarumma (2024)
  7. Nisin-A lantibiotic with immunomodulatory properties: A review.
    Joanna Małaczewska, Edyta Kaczorek-Łukowska (2021) - Peptides
  8. Synergistic effect of the coculture of Leuconostoc pseudomesenteroides and Lactococcus lactis, isolated from honeybees, on the generation of plant-based dairy alternatives based on soy, pea, oat, and potato drinks.
    Guillermo Eduardo Sedó Molina, Radhakrishna Shetty, Charlotte Jacobsen, Lene Duedahl-Olesen, Egon Bech Hansen, Claus Heiner Bang-Berthelsen (2024) - Food microbiology
  9. Remolding probiotics for effective treatment of type 2 diabetes via oral administration.
    Haihua Ji, Yiqun Wan, Shengjie Li, Dexi Zhou, Fengying Gu, Jiajiu Sun, Xiaochen Yan, Yu Le, Tingtao Chen, Shaoping Nie, Hao Wan (2025) - Biomaterials
  10. Whole-genome sequence analysis and probiotic characteristics of Lactococcus lactis Subsp. lactis strain Lac3 isolated from traditional fermented buffalo milk (Dadih).
    Nshimiyimana Sylvere, Apon Zaenal Mustopa, Sri Budiarti, Lita Meilina, Ai Hertati, Ira Handayani (2023) - Journal, genetic engineering & biotechnology
  11. Immunoregulatory effects of Lactococcus lactis-derived extracellular vesicles in allergic asthma.
    Dong-Hyun Lee, Han-Ki Park, Hee-Ra Lee, Hyeukjun Sohn, Soyoon Sim, Hyeon Ju Park, Yoo Seob Shin, Yoon-Keun Kim, Youngwoo Choi, Hae-Sim Park (2022) - Clinical and translational allergy
  12. Immunomodulatory action of Lactococcuslactis.
    Lejaniya Abdul Kalam Saleena, Michelle Yee Mun Teo, Yu Hsuan How, Lionel Lian Aun In, Liew Phing Pui (2023) - Journal of bioscience and bioengineering
  13. Probiotics in tilapia (Oreochromis niloticus) culture: Potential probiotic Lactococcus lactis culture conditions.
    Juan Andrés Cano-Lozano, Luisa Marcela Villamil Diaz, Javier Fernando Melo Bolivar, Michael E Hume, Ruth Yolanda Ruiz Pardo (2022) - Journal of bioscience and bioengineering
  14. Mucosal vaccination and therapy with genetically modified lactic acid bacteria.
    Jerry Wells (2011) - Annual review of food science and technology
  15. Antimicrobial Activity of Peptides Produced by
    Fernando M M Sanca, Iago R Blanco, Meriellen Dias, Andrea M Moreno, Simone M M K Martins, Marco A Stephano, Maria A Mendes, Carlos M N Mendonça, Wellison A Pereira, Pamela O S Azevedo, Martin Gierus, Ricardo P S Oliveira (2023) - Animals : an open access journal from MDPI
  16. Enhancing the biosynthesis of nicotinamide mononucleotide in Lactococcus lactis by heterologous expression of FtnadE.
    Ling-Hui Kong, Tai-Yu Liu, Qing-Shou Yao, Xiao-Hua Zhang, Wei-Na Xu, Jia-Yang Qin (2023) - Journal of the science of food and agriculture
  17. Health-Promoting Nature of
    Przemysław Sałański, Magdalena Kowalczyk, Jacek K Bardowski, Agnieszka K Szczepankowska (2022) - Frontiers in microbiology
  18. Combinational Antibacterial Activity of Nisin and 3-Phenyllactic Acid and Their Co-production by Engineered
    Jiaheng Liu, Rongrong Huang, Qianqian Song, Hui Xiong, Juan Ma, Rui Xia, Jianjun Qiao (2021) - Frontiers in bioengineering and biotechnology
  19. Prevention and control of chicken coccidiosis construction of recombinant Lactococcus lactis expressing chicken IL-4 and IL-2 fusion protein and its immune synergistic effect on chicken coccidia live vaccine.
    Longlong Zheng, Li Zhang, Fan Tan, Chen Wang, Xiaoling Lv, Rui Bai, Nairui Huo, Mingxue Zheng (2023) - Poultry science
  20. Novel Strategies for Efficient Production and Delivery of Live Biotherapeutics and Biotechnological Uses of
    Laísa M Tavares, Luís C L de Jesus, Tales F da Silva, Fernanda A L Barroso, Viviane L Batista, Nina D Coelho-Rocha, Vasco Azevedo, Mariana M Drumond, Pamela Mancha-Agresti (2020) - Frontiers in bioengineering and biotechnology


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!